ESC-HFA 2023: Late-Breaking Science Video Collection
Published: 23 May 2023
-
Views:
3160
-
Likes:
7
-
Views:
3160
-
Likes:
7
-
Up Next -
3m 11sPart 2 | Session 3 APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis -
4m 45sPart 2 | Session 4 DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction -
8m 47sPart 2 | Session 5 DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF -
4m 53sPart 2 | Session 6 NUDGE-FLU: Increasing Influenza Vaccination in HF Patients -
3m 56sPart 2 | Session 7 DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF -
5m 11sPart 2 | Session 8 TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure -
8m 22sPart 2 | Session 9 Diagnosis in Heart Failure in Women -
3m 50sPart 2 | Session 10 Dapagliflozin and Peripheral Arterial Disease in Heart Failure
-
26m 30sPart 1 | Session 1 Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Harriette Van Spall, Tariq Ahmad, Jozine ter Maaten
-
5m 48sPart 1 | Session 2 The PARAGLIDE-HF Trial Harriette Van Spall, Robert Mentz
-
13m 32sPart 1 | Session 3 HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Harriette Van Spall, James L Januzzi
-
4m 3sPart 1 | Session 4 TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction James L Januzzi, Harriette Van Spall
-
2m 45sPart 2 | Session 1 MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring Jasper J Brugts
Overview
Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.
Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.
For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826).
This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that aficamten treatment was well-tolerated in patients with nHCM, supporting further study of the drug in a phase 3 trial.
Interview Questions:
- What is currently understood about the pathophysiology of nHCM and what treatment options are available in 2023?
- How does Aficamten, a selective inhibitor of cardiac myosin, work?
- What was the study design, patient population, and outcome measures of REDWOOD-HCM-Cohort 4?
- What data was presented at the HFA and what conclusions can be drawn from the findings?
- What safety considerations and adverse events were observed?
- What are the next steps in research or clinical development?
Faculty Biographies
Ahmad Masri
Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.
He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.
Comments